GSK Veteran Paul Wren Joins Escape Bio as Chief Scientific Officer

Escape Bio, a biotech developing therapies for neurodegenerative disorders, has appointed Paul Wren to serve as its chief scientific officer. Wren was most recently senior director of neuroscience discovery at GlaxoSmithKline (NYSE: [[ticker:GSK]]). His experience also includes positions at Pfizer (NYSE: [[ticker:PFE]]) and Novartis (NYSE: [[ticker:NVS]]) subsidiary Sandoz.

The most advanced program from San Francisco-based Escape (formerly known as E-Scape Bio) is ESB1609. The experimental treatment is in Phase 1 testing for Niemann-Pick type C, a lysosomal storage disorder.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan